{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:51:09Z","timestamp":1790257869789,"version":"4.1.0"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T00:00:00Z","timestamp":1032220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the HER2 protein. Cardiotoxicity has been reported to occur with trastuzumab when administered alone and in combination with antineoplastic agents, particularly anthracyclines. The risk of cardiotoxicity with trastuzumab has been reported to be 4% with monotherapy and 27% when administered in combination with an anthracycline and cyclophosphamide, but to the author's knowledge severe outcomes, such as death or permanent disability, are uncommon. The majority of reported cardiac effects are mild to moderate, nonspecific, and medically manageable. Signs and symptoms are similar to those observed in patients who develop anthracycline\u2010induced cardiomyopathy and include tachycardia, palpitations, and exertional dyspnea, which may progress to congestive heart failure. The pathogenesis and histologic changes responsible for trastuzumab\u2010associated cardiotoxicity currently are under investigation. Unlike anthracycline\u2010induced toxicity, trastuzumab\u2010associated toxicity usually responds to standard treatment or the discontinuation of trastuzumab, and there is no evidence that the toxicity is dose related. Current methods for the early detection of cardiotoxicity in trastuzumab\u2010treated patients are similar to those used in anthracycline\u2010treated patients. Cardiac function is established at baseline and monitored regularly during treatment by physical examination and measurement of left ventricular ejection fraction. The majority of patients improve with proper treatment, and some are able to continue to receive trastuzumab. Cancer 2002;95:1592\u2013600. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10854<\/jats:p>","DOI":"10.1002\/cncr.10854","type":"journal-article","created":{"date-parts":[[2002,10,8]],"date-time":"2002-10-08T22:18:17Z","timestamp":1034115497000},"page":"1592-1600","source":"Crossref","is-referenced-by-count":282,"title":["Trastuzumab\u2010associated cardiotoxicity"],"prefix":"10.1002","volume":"95","author":[{"given":"Deborah L.","family":"Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,9,17]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/08977199409010997"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.1996.0019"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.1.103"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.103"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1044"},{"key":"e_1_2_10_9_2","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski MX","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"e_1_2_10_12_2","first-page":"78","article-title":"Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu\u2010overexpressing metastatic breast cancer","volume":"26","author":"Baselga J","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_10_13_2","first-page":"232","article-title":"Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials","volume":"50","author":"Hudis C","year":"1998","journal-title":"Breast Cancer Res Treat."},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2659"},{"key":"e_1_2_10_15_2","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman A","year":"2002","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.719"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)81715-8"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90189-7"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2587"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2722"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2001.22815"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.81.4.419"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809243391307"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921201)70:11<2637::AID-CNCR2820701112>3.0.CO;2-P"},{"key":"e_1_2_10_25_2","first-page":"996","article-title":"Trastuzumab and breast cancer","volume":"345","author":"Strasser F","year":"2001","journal-title":"N Engl J Med."},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/378394a0"},{"key":"e_1_2_10_27_2","first-page":"102a","article-title":"HER2 expression in the myocardium as a cause for cardiotoxicity of trastuzumab (Herceptin)?","volume":"19","author":"Fuchs I","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_10_28_2","first-page":"96","article-title":"Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?","volume":"26","author":"Ewer MS","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_10_29_2","first-page":"9","article-title":"Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity","volume":"27","author":"Chien KR","year":"2000","journal-title":"Semin Oncol."},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80043-4"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00469-6"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.6.495.35164"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1425"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1435"},{"key":"e_1_2_10_36_2","first-page":"12","article-title":"A population pharmacokinetic model for trastuzumab following weekly dosing","volume":"71","author":"Washington CB","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109273451312"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10854","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:10:14Z","timestamp":1760281814000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,17]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1002\/cncr.10854"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10854","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,17]]}}}